Nirsevimab and Maternal Respiratory Syncytial Virus Vaccine Recommendations for the Pediatric Population.

IF 1.1 4区医学 Q3 PEDIATRICS

Pediatric Annals Pub Date : 2025-05-01 DOI:10.3928/19382359-20250307-02

Anusha Panjwani, Jennifer S Katz, Robert K Katz

引用次数: 0

Abstract

For infants up to age 12 months, there is an urgent need for protection against respiratory tract infection caused by respiratory syncytial virus (RSV). Nirsevimab (Beyfortus [Sanofi (Bridgewater, NJ), AstraZeneca (Wilmington, DE)], a long-acting monoclonal antibody for infants, and the bivalent RSV prefusion F (RSVpreF) vaccine (ABRYSVO [Pfizer (New York, NY)]) for pregnant women are the current recommendations for protection against RSV. This review summarizes current evidence-based practices for these interventions, highlights recommendations for delivery, and addresses challenges faced by providers during the RSV season. [Pediatr Ann. 2025;54(5):e160-e166.].

查看原文本刊更多论文

尼塞维单抗和母体呼吸道合胞病毒疫苗对儿科人群的建议。

对于12个月以下的婴儿，迫切需要预防呼吸道合胞病毒（RSV）引起的呼吸道感染。Nirsevimab (Beyfortus [Sanofi (Bridgewater， NJ), AstraZeneca (Wilmington， DE)]，一种用于婴儿的长效单克隆抗体，以及用于孕妇的二价RSV预融合F （RSVpreF）疫苗（ABRYSVO [Pfizer (New York， NY)]）是目前针对RSV的保护推荐。本综述总结了目前这些干预措施的循证实践，重点介绍了实施建议，并解决了在呼吸道合胞病毒流行季节提供者面临的挑战。[j].儿科学，2025;54(5):e160-e166。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Annals 医学-小儿科

CiteScore

1.80

自引率

0.00%

发文量

104

审稿时长

2 months

期刊介绍： Published for more than 40 years, Pediatric Annals is an online-only, monthly medical review journal dedicated to providing pediatricians and other clinicians with the latest practical information on the diagnosis and treatment of pediatric diseases and disorders. Begin to explore the Journal and all of its great benefits such as: -Single-topic summary reviews of important trends in pediatric medicine -Access to current articles, as well as several years of archived content -Columns including Healthy Baby/Healthy Child and Case Challenges